Incidence of UL97 Resistance Mutations in Infants with Congenital Cytomegalovirus Disease Receiving 6 Months of Oral Valganciclovir Therapy

BACKGROUND: A recently completed Phase 3 randomized, controlled, double-blind, multicenter study of infants with symptomatic congenital cytomegalovirus (CMV) disease receiving 6 months of oral valganciclovir (VGCV) therapy represents the largest such population in which to evaluate treatment-emergen...

Descripción completa

Detalles Bibliográficos
Autores principales: James, Scott H, Conner, Ra’Shun L, Kimberlin, David W, Whitley, Richard, Prichard, Mark N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631963/
http://dx.doi.org/10.1093/ofid/ofx162.058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631963/
http://dx.doi.org/10.1093/ofid/ofx162.058

Ejemplares similares